Fig. 2.

AGTR2 agonist rescues microglia activation and memory decline. A Schematic timeline of experiment. Control and LPS/MV-stimulated mice were pre-treated with vehicle, and LPS/MV-stimulated mice pre-treated with different concentrations of C21 were designated as LPS/MV + C21 (0.03, 0.3, and 3 mg/kg) groups. B The results of Iba1 immunostaining and 3D reconstruction of microglia in the mPFC was shown. Scale bars, 40 μm (overview) and 10 μm (Zoom and Rendering). C Quantification of Iba1⁺ number, intensity, soma size, and Iba1⁺ microglia morphometry was measured by Imaris-based semi-automatic quantification in the mPFC. D The results of Iba1 immunostaining and 3D reconstruction of microglia in the hippocampus was shown. Scale bars, 40 μm (overview) and 10 μm (Zoom and Rendering). E Quantification of Iba1⁺ number and intensity in the hippocampus. F Quantification of Iba1⁺ soma size, and Imaris-based semi-automatic quantification of Iba1⁺ microglia morphometry in the hippocampus. G The results of FCT was analysed in Veh and C21-treated mice. H The results of OFT was analysed in Veh and C21-treated mice. All data were presented as mean ± SEM. * p < 0.05; ** p < 0.01; *** p < 0.001; ns, not significant. For detailed statistics information, see Table S1. Abbreviations: AGTR2, angiotensin type 2 receptor; Veh, vehicle; C21, compound 21